Core Insights - Scienture Holdings, Inc. has appointed Michele Rath as Senior Vice President and Chief Commercial Officer of its subsidiary, Scienture, LLC, to enhance its commercial operations and market reach [1][2] - The company has established a strategic partnership with Syneos Health, which will act as its Contract Sales Organization, aiming to leverage Syneos Health's expertise in outsourced sales solutions [1][3] Company Overview - Scienture Holdings, Inc. operates through its subsidiaries, focusing on providing novel specialty pharmaceutical products to meet unmet market needs [5] - Scienture, LLC is dedicated to developing and marketing unique specialty products, with a team experienced in the pharmaceutical industry [5] Leadership and Strategy - Michele Rath brings over 20 years of experience from leading roles at Pfizer, CVS Caremark, and Aurobindo Pharma, focusing on sales strategy and market access [2] - Under Rath's leadership, Scienture, LLC aims to drive revenue growth, strategic partnerships, and customer engagement [2] Collaboration with Syneos Health - The partnership with Syneos Health will enhance Scienture, LLC's commercial capabilities through a comprehensive suite of services, including field sales and tech-enabled engagement strategies [3] - Syneos Health's Kinetic platform will provide predictive and adaptive analytics to streamline commercial solutions for Scienture, LLC [3] Product Launches - Scienture, LLC is preparing to launch two FDA-approved products: Arbli (losartan potassium) oral suspension and Rezenopy (naloxone HCl) nasal spray, with expectations of accelerated growth through the new commercial strategies [4]
SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization